April 2019 Vol XLIII Issue 4
INFLAMMATORY BOWEL DISEASE: A PRACTICAL APPROACH, SERIES #106
The IBD Therapeutic Pipeline Is Primed To ProduceThere has not been a more exciting time in the treatment of inflammatory bowel disease (IBD) since the approval of infliximab in 1998. In addition to multiple recently approved medications including vedolizumab, ustekinumab, and recently tofacitinib, the IBD pipeline continues to expand at a remarkable rate. This review will provide an update on the current and future IBD drugs, focusing on promising therapies currently in late stage or advanced human clinical trials.
NUTRITION ISSUES IN GASTROENTEROLOGY, SERIS #185
Part III Jejunal Enteral Feeding: The Tail is Wagging the Dog(ma) Dispelling Myths with Physiology, Evidence, and Clinical ExperienceJejunal feeding is the next best option for patients who cannot tolerate gastric feedings and would otherwise be placed on parenteral nutrition. Yet, it remains beleaguered by dogmatic rules with very little substantiating evidence or conformity with physiology. Part III of this enteral series serves to dispel some of the long-standing myths that are still widely practiced today and result in unsuccessful jejunal feeding.
FRONTIERS IN ENDOSCOPY, SERIES #51
Pancreaticopleural Fistula: Diagnosis and Management of Three CasesPancreaticopleural fistulas are uncommon complications of pancreatitis that occur when there is a disruption in the pancreatic duct, causing pancreatic fluid to track through the retroperitoneum and into the pleural cavities. Treatment of pancreaticopleural fistulas can include conservative medical therapy, ERCP intervention using pancreatic duct stent, and operative therapy which should be considered a last resort if all prior therapies fail. This manuscript serves to highlight why ERCP with pancreatic duct stenting should be considered first line therapy when treating a pancreaticopleural fistula.
DISPATCHES FROM THE GUILD CONFERENCE, SERIES #21
Biosimilars for the Treatment of Inflammatory Bowel DiseaseBiosimilars are biologic products that are highly similar to a previously approved reference (or originator) biologic drug in terms of safety, purity, and potency (efficacy). These medications are increasingly being approved by global regulatory agencies in the hopes of reducing treatment costs. This review aims to answer common questions regarding biosimilars and their use for IBD. It is written in a question/answer format for easy reference and guides the reader from the basics of biosimilars, to clinically relevant questions encountered in the clinic, to their policy implications, among other topics.
FELLOWS’ CORNER
A Case of Small Bowel Intussusception in an AdultDepartments Section
Common Sense Pediatric Gastroenterology: A Practical Guide
Common Sense Pediatric Gastroenterology: A Practical Guide, authored by Dr. Tim Blaufuss, was envisioned during a home call, when he identified the need for a resource for common pediatric gastroenterology related clinical questions. Dr. Blaufuss recently completed his pediatric gastroenterology fellowship at Children's Mercy Hospital, Kansas City, MO, and has joined Sanford Health, Fargo, ND. This book primarily targets pediatric gastroenterology trainees; however, pediatricians, residents and current pediatric gastroenterologists also will find this book beneficial.
Screening for Pancreatic Cancer
A meta-analysis of prospective cohort studies to determine the diagnostic yield and outcomes of abdominal imaging screening for asymptomatic individuals at high risk for pancreatic cancer, based on family history or genetic variants was carried out.
Assessment of Fibrosis and Steatosis in NAFLD
To determine the diagnostic accuracy of vibration controlled transient elastography (VCTE), which measures liver stiffness, a prospective study of 393 adults with NAFLD was carried out within one year of liver histology analysis from 7/1/2014 through 7/31/2017.
Transient Elastography in Apparently Healthy Individuals and Changes in Liver Stiffness
A systematic review was carried out to determine the range of liver stiffness measurements (LSMs) examined by transient elastography in healthy individuals and individuals who are susceptible to fibrosis. Data was collected from 16,082 individuals in 26 cohorts, identified from systematic searches of MBASE, Ovid MEDLINE, Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews for studies of liver stiffness measurements.
Thermal Ablation of Endoscopic Mucosal Resection
Endoscopic mucosal resection (EMR) is performed to remove large laterally spreading colonic lesions with a high risk of progression to CRC. Because endoscopically invisible micro-adenomas at the margins of the EMR site might contribute to adenoma recurrence that occurs at 15-30% of patients who undergo surveillance, determination of the efficacy of adjuvant thermal ablation of the EMR mucosal defect margin in reducing polyp recurrence was carried out.
Preventing Perinatal Transmission of Hepatitis C
Hepatitis C virus (HCV) infection is increasing in young adults, and better screening processes during pregnancy are warranted in order to prevent a subsequent increase in HCV infections in newborns. The authors used data from the Recovery, Empowerment, Social Services, Prenatal care, Education, Community, and Treatment (RESPECT) project from Boston Medical Center which cares for pregnant women with substance use disorders.
Are We Forgetting to Do Long-Term Follow Up for Children with Celiac Disease
Celiac disease (CD) or gluten-sensitive enteropathy requires life-long adherence to a gluten-free diet as non-adherence can have significant health consequences. The authors of this study evaluated how well children with CD were followed longterm by determining how often such children received follow-up care defined as meeting with a dietician as well as annual disease-specific care.
VEDOLIZUMAB (ENTYVIO®) ACHIEVES SUPERIOR RATES OF CLINICAL REMISSION VS. ADALIMUMAB (HUMIRA®) IN FIRST EVER HEAD-TO-HEAD BIOLOGIC CLINICAL STUDY IN ULCERATIVE COLITIS
Vedolizumab superior to adalimumab in achieving clinical remission and mucosal healing at week 52 in patients with moderately to severely active ulcerative colitis
LABCORP STRENGTHENS LEADERSHIP POSITION IN PRECISION MEDICINE WITH EXPANSION OF THERAPEUTIC DRUG MONITORING PORTFOLIO
LabCorp’s DoseASSURE® Portfolio Provides Most Expansive Biologics TDM Menu Combined with Expert Guidance
May 3, 2019 Functional GI and Motility Disorders: A Comprehensive and Practical Approach
May 18-21, 2019 Digestive Disease Week (DDW)
July 15-19, 2019 41st Annual Aspen Conference on Pediatric Gastrointestinal Disease: Pediatric Gastrointestinal Disease and Small Bowel Transplantation
October 25-30, 2019 American College of Gastroenterology (ACG) 2019 Annual Scientific Meeting and Postgraduate Course
